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Abstract: 
With the Entamoeba genome essentially complete, the organism can be studied from a whole genome standpoint. The 
understanding of cellular mechanisms and interactions between cellular components is instrumental to the development of 
new effective drugs and vaccines. Metabolic pathway analysis is becoming increasingly important for assessing inherent 
network properties in reconstructed biochemical reaction networks. Metabolic pathways illustrate how proteins work in 
concert to produce cellular compounds or to transmit information at different levels. Identification of drug targets in E. 
histolytica through metabolic pathway analysis promises to be a novel approach in this direction. This article focuses on the 
identification of drug targets by subjecting the Entamoeba genome to BLAST with the e-value inclusion threshold set to 
0.005 and choke point analysis. A total of 86.9 percent of proposed drug targets with biological evidence are chokepoint 
reactions in Entamoeba genome database.  
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Background: 
The amitochondrial protist Entamoeba histolytica, lacking 
both mitochondria and hydrogenosomes [1] is estimated to 
infect up to 10 percent of the world’s population. Fifty 
million cases of amoebic dysentery and liver abscess are 
reported each year. [2] Between 40 and 100 thousand 
people die of amoebiasis each year. [3] Among parasitic 
infections, amoebiasis caused by E. histolytica ranks third 
worldwide, behind malaria and schistosomiasis, in lethal 
infections. 
 
With the Entamoeba genome essentially complete [4] the 
organism can be studied from a whole genome standpoint. 
The knowledge of cellular mechanisms and interactions 
between cellular components is instrumental to the 
development of new effective drugs and vaccines. 
Metabolic pathways illustrate how proteins work in concert 
to produce cellular compounds or to transmit information at 
different levels. The view provided by the E. histolytica 
genome sequence is remarkable as it assists in the 
reconstruction of its metabolism and in the development of 
new antiamoebic drugs through the identification of its 
enzymes. The metabolism of E. histolytica has been shaped 
by an influx of bacterial genes through lateral gene transfer. 
[4]  
 
Metabolic pathway analysis is very useful as it allows 
determining the overall capacity, i.e., theoretical maximum 
yield, of a cellular system and studying effects of any 
genetic modification. However, pathway analysis of large 
and highly entangled metabolic networks meets the 
problem of combinatorial explosion of possible routes 
across the networks. Here we propose a method to cope 
with this problem by two methods. In the present work, it 
has been tried to focus on the identification of drug targets 
by subjecting the Entamoeba genome to BLAST with the 
e-value inclusion threshold set to 0.005 and choke point 
analysis. 
 
Methodology: 
Identification of potential drug targets through two 
methods 
One feature that one can expect a good drug target to have 
is a lack of similarity to any human enzyme. The E. 
histolytica genome sequence is available from GenBank or 
from The Institute for Genomic Research website 
(http://www.tigr.org/tdb/e2k1/eha1/).  KEGG [5] pathway 
database was used as a source of metabolic pathway 
information. Metabolic pathway identification numbers of 
the host H. sapiens and the pathogen E.histolytica were 
extracted from the KEGG database. Pathways which do not 
appear in the host but present in the pathogen according to 
KEGG database annotation have been identified as 
pathways unique to E.histolytica as compared to the host H. 
sapiens. The corresponding protein sequences were 
retrieved from the KEGG database. They were subjected to 
a BLASTp [6] search against the non-redundant database Bioinformation by Biomedical Informatics Publishing Group  open access 
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with the e-value inclusion threshold set to 0.005. The 
search was restricted to proteins from H. sapiens through 
an option available in the BLAST program, which allows 
the user to select the organism to which the search should 
be restricted. In the current context, the objective is to find 
only those targets, which do not have detectable human 
homologues. Enzymes, which do not have hits below the e-
value inclusion threshold of 0.005, were picked out as 
potential drug targets. 
 
Choke point analyses 
Cells, whether free-living or as components of an organism, 
are regularly exposed to stimuli and perturbations to which 
they have to respond in a coordinated fashion. Such 
responses may vary widely in the numbers and types of 
identifiable steps that begin with sensing the stimulus and 
end with a change in biochemistry or physiology. 
Metabolic reconstruction of the organism can help in this 
direction. It is the purpose of this article to introduce 
alternative measures for this task and hence, the choke 
point analysis was one such measure. Here the choke point 
analysis method of Yeh et al. [7] has been adopted. It is 
being described below: 
 
To identify potential drug targets, a chokepoint analysis of 
the metabolic network of E.histolytica is performed. A 
“chokepoint reaction” is a reaction that either uniquely 
consumes a specific substrate or uniquely produces a 
specific product in the Entamoeba  metabolic network 
(Figure 1). As described by Yeh and colleagues [7] it is 
expected that the inhibition of an enzyme that consumes a 
unique substrate result in the accumulation of the unique 
substrate which is potentially toxic to the cell and the 
inhibition of an enzyme that produces a unique product to 
result in the starvation of the unique product which 
potentially cripple essential cell functions. Thus, it is 
believed that chokepoint enzymes may be essential to the 
parasite and are therefore potential drug targets.  
 
Chokepoint analysis has several advantages. First, it allows 
us to test the consistency between experimental data and 
assumptions about the organization and regulation of the 
biochemical pathway and of its interdependencies with 
other processes. Second, it can be used to predict the 
consequences of various mutations or inhibitors. 
 
Results and discussion: 
The targeting of metabolic pathways has several 
advantages on its own. Each step in the pathway is well 
validated as an essential function for pathogen growth. The 
target enzymes from the pathogen which are discarded and 
which share a similarity with the host proteins ensures that 
the targets have nothing in common with the host proteins, 
thereby, eliminating undesired host protein–drug 
interactions. Metabolic pathway analysis is becoming 
increasingly important for assessing inherent network 
properties in reconstructed biochemical reaction networks. 
 
Figure 1: The thick arrows represent reactions that are 
catalyzed by enzymes, whereas the thin arrows represent 
reactions that are present (no evidence of the corresponding 
enzymes). While determining chokepoint reactions, only 
the catalyzed reaction are considered 
 
Pathways unique to E. histolytica when compared to the 
host H. sapiens 
An important question to be addressed while choosing 
potential drug targets is whether the biochemical pathway 
to be targeted is unique to pathogen. The three pathways 
addressed in this study: peptidoglycan biosynthesis, 
streptomycin biosynthesis, and thiamine metabolism which 
are unique to the pathogen E.histolytica  are discussed. 
Enzymes, from these pathways, which do not show 
similarity to any of the host proteins, are listed in Table 1 
(supplementary material). 
 
Peptidoglycan biosynthesis 
Entamoeba histolytica was found to grow normally without 
producing glutathione and the main enzymes of glutathione 
metabolism, indicating that glutathione is not essential for 
many eukaryotic processes. This parasitic amoeba is an 
unusual eukaryote whose special features may help define 
the crucial functions of glutathione in those eukaryotes that 
do use it. Since Entamoeba histolytica lacks mitochondria 
and the usual aerobic respiratory pathways, the finding that 
it grows without glutathione and other evidence support the 
hypothesis that a primary function of glutathione in 
eukaryotes involves protection against oxygen toxicity 
associated with mitochondria and suggest that eukaryotes 
may have acquired glutathione metabolism at the time that 
they acquired mitochondria. [8] If this hypothesis is true, 
then the genes for GSH biosynthesis in eukaryotes should 
resemble those from alpha-proteobacteria, the modern 
relatives of the mitochondrial progenitor. [9, 10] 
 
Thiamine metabolism 
The electrophoretic patterns of hexokinase and 
phosphoglucomutase strongly support the redefinition of 
pathogenic and nonpathogenic Entamoeba histolytica as 
two closely related species Entamoeba histolytica and 
Entamoeba dispar. [11] Thiamin pyrophosphokinase (TPK) Bioinformation by Biomedical Informatics Publishing Group  open access 
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catalyses the transfer of a pyrophosphate group from ATP 
to vitamin B1 (thiamin) to form the coenzyme thiamin 
pyrophosphate (TPP). Thus, TPK is important for the 
formation of a coenzyme required for central metabolic 
functions. The structure of thiamin pyrophosphokinase 
suggests that the enzyme may operate by a mechanism of 
pyrophosphoryl transfer similar to those described for 
pyrophosphokinases functioning in nucleotide biosynthesis. 
[12] 
 
Streptomycin biosynthesis 
Glycosylphosphatidylinositol (GPI)-anchored molecules 
such as
  cell surface Gal/GalNAc lectin and 
proteophosphoglycans of the
 protozoan parasite Entamoeba 
histolytica are thought to be involved
 in pathogenesis. [13] 
The cells of E.histolytica contained inorganic phosphate, 
pyrophosphate, nucleoside diphosphates, nucleoside 
triphosphates, NAD(P), phosphocholine, 
phosphoethanolamine, cytidine 5'-diphosphocholine
  and 
cytidine 5'- diphosphoethanolamine . The latter four 
compounds may act as intermediates in the salvage
 
pathway for the synthesis of phosphatidylethanolamine and
 
phosphatidylcholine. [14]   
 
Carbohydrate metabolism  
Studies have shown that E.histolytica grow or survive 
better in media containing glucose than in glucose deficient 
media, which is consistent with carbohydrates being the 
main energy substrates for anaerobic protists. 
Carbohydrates are the main source of energy for the 
parasite. The pathway involved in the fermentation of 
glucose includes some unusual enzymes that use 
pyrophosphate (PPi) rather than a nucleoside triphosphate 
as the phosphate donor. [15] Many of the genes encoding 
enzymes of the glycolytic pathway have been cloned and 
sequenced. Both D- glucose and D-galactose are 
transported and actively metabolized by E.histolytica. [15] 
 
Lipid metabolism 
Little is known about lipid metabolism in Entamoeba. 
Three phospholipase activities A1, A2 and L1 have been 
detected. [16]  Entamoeba can also synthesise cholesterol 
and isoprenoids. [17] The only detectable polyamine 
present is putrescine at 9.5mM. [18] As it is present only in 
trace amounts in the growth medium, the amoeba must 
therefore synthesize it. 
 
Protein metabolism 
Protein metabolism in Entamoeba is not clearly elucidated. 
Amino acid utilization studies [19]  showed that certain 
amino acids such as arginine, threonine, leucine, glutamine, 
phenylalanine and isoleucine could serve as an alternative 
energy source in the absence of glucose. The organism 
synthesizes cysteine, as cysteine synthase. [20] 
 
Choke point analyses 
If an enzyme catalyzes at least one chokepoint reaction, it 
is classified as a potential drug target. All the potential 
metabolic drug targets are listed in Table 2 (supplementary 
material). To assess the usefulness of identifying 
chokepoint enzymes for proposing drug targets, 
chokepoints and nonchokepoints against proposed drug 
targets from the literature is compared. A complete 
literature search for proposed amoebiasis drug targets is 
attempted that were metabolic enzymes and met the criteria 
discussed above. Of the 23 proposed targets with biological 
evidence, 20 are chokepoints in Table 2 (supplementary 
material). A total of 86.9% of proposed drug targets with 
biological evidence are chokepoint reactions in Entamoeba 
genome database. Chokepoints may not be essential. One 
reason could be that they create unique intermediates to an 
essential product which are not essential themselves and 
finally, there could be chokepoint reactions that are not 
essential due to other pathways that achieve the same 
metabolic goal within the organism. One example could be 
blocking the reaction that has no deleterious effects on the 
parasite. [7] 
 
Due to the high percentage of enzymes identified as choke 
points, one  additional criteria observed in addition to being 
a choke point enzyme for identifying potential metabolic 
drug targets is that an enzyme not having isozymes would 
make it more likely to be a good drug target. This is 
because one enzyme would be easier to inhibit than a 
family of enzymes. As for example, methionine γ - lyase in 
E. histolytica has two isozymes [40] and according to the 
criteria outlined above, it has not been included in the list 
of potential drug targets identified in Table 2 
(supplementary material). 
 
There are further aspects on which the list of potential drug 
targets can be narrowed down. The drug should adversely 
affect the parasite but not the human host which means that 
if the drug target has a homologous enzyme in human, it 
should not be essential or have differential inhibition in 
human. In other way, it can be said that potential drug 
targets should be expressed in the human stages of the 
parasite. The two most promising concepts for pathway 
analysis focused here are closely related. Assessing 
metabolic systems by the set of extreme pathways can, in 
general, give misleading results owing to the exclusion of 
possibly important routes. A full assessment of the 
proposed listed steps will require intense further effort. It is 
to be expected that some experiments may be significant 
which will stimulate the next phase of amendments and 
refinements. As it stands, it is hoped to serve the scientific 
community as a starting point for further data collection 
and experimentation in concert with, and based on, 
pathway analysis. 
 
Conclusion 
The genome sequence of E. histolytica has provided greater 
in-depth facts revealing that many pathways normally 
present in eukaryotes are absent from this organism. In 
addition, by identifying choke point reactions, 
identification of enzymes has been done that are essential 
to the parasite’s survival. There is an enrichment of drug 
targets in chokepoints as compared with non-chokepoints. Bioinformation by Biomedical Informatics Publishing Group  open access 
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This leads to the conclusion that the classification of an 
enzyme as a chokepoint has some bearing on whether or 
not it would make a good drug target. The capabilities of 
the parasite to transport an accumulating metabolite out of 
the cell or a limiting metabolite into the cell have not been 
considered. It further limits the choke point analysis. The 
provisional targets which have been cited here needs to be 
examined further, both computationally and experimentally 
for these additional features. It can be said that biochemical 
reaction systems have become an important approach for 
understanding the functionality of metabolic networks 
reconstructed by genomic and biochemical data. 
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Supplementary material 
 
Genbank accession No.  Gene  Description 
Peptidoglycan biosynthesis: KEGG pathway ID ehi00550 
EAL50404            23.t00033  glutamine synthatase,putative 
Thiamine metabolism: KEGG pathway ID ehi00730 
EAL50105     28.t00019       myotubularin, putative                                                    
EAL44953        226.t0008      inosine triphosphate pyrophosphatase, putative 
EAL52121     1.t00126     thiamine pyrophosphokinase,putative 
Streptomycin biosynthesis: KEGG pathway ID ehi00521 
EAL50580     19.t00020       hexokinase                                                                            
EAL44377       273.t00008  L-myo-inositol-phosphate synthase 
EAL45227  208.t00004     myo-inositol monophosphatase,putative 
EAL51122     11.t00065  dTDP-D-glucose 4, 6-dehyratase,putative 
Table 1: Targets from unique pathways, which do not have human homologue  
 
Target enzyme               EC number       Reference  Choke point  In Human 
Thymidylate synthase                                    2.1.1.45  [21]  Yes Yes 
Thioredoxin reductase                                   1.8.1.9  [22]  No Yes 
Succinate dehydrogenase                               1.3.99.1  [23]  No Yes 
Sphingomyelinase 3.1.4.12  [24]  Yes No 
S-adenosylmethionine decarboxylase           4.1.1.50  [25]  Yes Yes 
S-adenosyl-L-homocysteine hydrolase         3.3.1.1  [26]  Yes Yes 
RNA polymerase                                           2.7.7.6  [27]  Yes Yes 
Purine nucleoside phosphorylase                  2.4.2.1  [28]  Yes No 
NADH dehydrogenase (ubiquinone)             1.6.5.3  [29]  Yes No 
Lysophospholipase      3.1.1.5  [16]  Yes No 
Lactoglutathione lyase                                   4.4.1.5  [30]  Yes Yes 
IMP dehydrogenase                                       1.2.1.14  [28]  No Yes 
Hypoxanthine phosphoribosyltransferase     2.4.2.8  [28]  Yes Yes 
Histone deacetylase                                         [31]  Yes Yes 
Gamma-glutamylcysteine ligase                   6.3.2.2  [32]  Yes Yes 
Fructose-bisphosphate aldolase                     4.1.2.13  [33]  Yes Yes 
Farnesyl diphosphate farnesyltransferase      2.5.1.21  [34]  Yes Yes 
Alcohol dehydrogenase  (NAD+)  1.1.1.1  [35]  Yes No 
DNA polymerase                             2.7.7.7  [36]  Yes Yes 
Chorismate synthase                                      4.2.3.5  [37], [38]  Yes No 
Choline transport                                             [14]  Yes No 
Carbamoyl-phosphate synthase                     6.3.5.5  [39]  Yes Yes 
3-oxoacyl-[acyl-carrier protein] synthase  2.3.1.41  [13]  Yes Yes 
Table 2: Drug targets proposed in the literature with biological evidence is given. The reaction and its EC number are 
given. The “In Human” column denotes whether or not the enzymatic activity has a similar enzyme in human as 
determined by BLAST alignment with an expectation of less than 0.0001. Of these 23 reactions, 20 (86.9 percent) were 
identified as chokepoints. 
 